000952 Hubei Guangji Pharmaceutical
- 6.22
- -0.13-2.05%
Hubei Guangji Pharmaceutical News
Guangji Pharmaceutical (000952.SZ): The company uses microbial fermentation to produce vitamin B2
Gelonghui, May 9 | Guangji Pharmaceutical (000952.SZ) said on the investor interactive platform that the company uses microbial fermentation to produce vitamin B2.
Guangji Pharmaceutical (000952.SZ) announced first-quarter results with a net loss of 50,5082 million
Guangji Pharmaceutical (000952.SZ) released its report for the first quarter of 2024, achieving an operating income of 1.8 during the reporting period...
Guangji Pharmaceutical (000952.SZ): Appoints Lu Zilong as General Manager
Gelonghui, April 12, 丨 Guangji Pharmaceutical (000952.SZ) announced that the company held the 40th (Provisional) Meeting of the 10th Board of Directors on April 12, 2024 to review and pass the “Proposal on Appointing Mr. Lu Zilong as the Company's General Manager”. Following the qualification review by the nomination committee of the 10th board of directors and the approval of the nominees, the board of directors of the company agreed to appoint Mr. Lu Zilong as the general manager of the company. The term of office will begin on the date of review and approval by the board of directors and end on the date of expiration of the 10th board of directors.
Guangji Pharmaceutical (000952.SZ) appoints Xiong Yi as financial director
Zhitong Finance App News, Guangji Pharmaceutical (000952.SZ) announced that the company's board of directors recently received a written resignation report submitted by the company's director and financial director Hu Mingfeng. Hu Mingfeng applied to resign as the company's financial director due to job changes. After his resignation, Hu Mingfeng continued to serve as the company's director. The company agreed to appoint Xiong Yi as the company's financial director. The term of office will begin on the date of review and approval by the board of directors until the end of the 10th board of directors.
Express News | Guangji Pharmaceutical: Expected net loss of 130 million to 165 million yuan in 2023
Guangji Pharmaceutical (000952.SZ) and related personnel received a warning letter from the Hubei Securities Regulatory Bureau
Guangji Pharmaceutical (000952.SZ) announced that the company recently received from the China Securities Regulatory Commission and the Hubei Regulatory Bureau...
Guangji Pharmaceutical Gets Nod to Produce Entecavir
Hubei Guangji Pharmaceutical (SHE:000952) obtained approval from China's National Medical Products Administration to produce the raw drug material Entecavir. The raw drug ingredient is used to treat a
Guangji Pharmaceutical (000952.SZ): Entecavir API marketing application approved
According to the Zhitong Finance App, Guangji Pharmaceutical (000952.SZ) announced that recently, the company received entecavir's “Notice of Approval of Marketing Application for Chemical Raw Materials” issued by the State Drug Administration. According to reports, entecavir is a guanine nucleoside analogue and has an inhibitory effect on hepatitis B virus polymerase. It is suitable for the treatment of chronic adult hepatitis B where virus replication is active, serum alanine aminotransferase (ALT) continues to rise, or liver histology shows active lesions.
[Instant Analysis of BT Financial Report] Guangji Pharmaceutical's 2023 Third Quarter Report: Net Assets Decreased Slightly, Balance Ratio Rise, and Net Profit Turned Negative
Announcement time of this financial report: 2023-10-20 16:03:14 Guangji Pharmaceutical (stock code: 000952) is a pharmaceutical manufacturing enterprise mainly engaged in R&D, production and sales of vitamin B2 and B6 raw material products and pharmaceutical products. The company has established an R&D center with APIs and formulations as the core and a number of supporting subsidiaries, and has developed into a modern pharmaceutical enterprise integrating R&D, production and sales. According to Guangji Pharmaceutical's financial summary for the third quarter of 2023, net assets at the end of the reporting period were 1,483 billion yuan, compared to 1,492 billion yuan at the end of the previous year
Guangji Pharmaceutical (000952.SZ) released its results for the first three quarters, with a net loss of 66.97762 million yuan, from profit to loss over the previous year
Guangji Pharmaceutical (000952.SZ) released its report for the first three quarters of 2023, with revenue of 522 million yuan, the same as...
Guangji Pharmaceutical (000952.SZ): The company is the main supplier of VB2 in the world, and the big health sector is a segment of layout
Glonghui, Oct. 17 | Guangji Pharmaceutical (000952.SZ) said on the investor interactive platform that the JD and Tmall stores are all online health products stores of Hubei Guangji Health Technology Co., Ltd., a wholly-owned subsidiary of the company; the company is a major global VB2 supplier, and the Big Health segment is a segment of the company's layout, not to benchmark Tomson Beijian. The Guangji Health team is intensively preparing for this year's online Double Eleven event.
Interpretation of Guangji Pharmaceutical's 2023 Interim Report: Total assets have grown significantly, and net profit is facing challenges
The 2023 interim report of Guangji Pharmaceutical (stock code: 000952) has been announced. The following is a detailed interpretation of its financial data. First, Guangji Pharmaceutical's revenue for the reporting period was 343,911,715.83 yuan, down 8.54% from 376,016,299.80 yuan in the same period last year. This is mainly due to the decline in sales volume of the leading product, which contains high content VB2, during the reporting period. Second, net profit attributable to shareholders of listed companies during the reporting period was -25,804,539.22 yuan, a decrease of 2 yuan compared with 24,696,168.47 yuan in the same period last year
Guangji Pharmaceutical (000952.SZ): Net loss of 258.045 million yuan in the first half of the year
Glonghui, August 30, 丨 Guangji Pharmaceutical (000952.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 344 million yuan, down 8.54% year on year; net profit attributable to shareholders of listed companies was -258.045 million yuan, year-on-year profit to loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -274.153,000 yuan; basic earnings per share were -0.0729 yuan.
Guangji Pharmaceutical (000952.SZ): Half year advance loss of 22.5 million to 29 million yuan, year-on-year profit to loss
On July 14, GLONGHUI | Guangji Pharmaceutical (000952.SZ) announced that net profit attributable to shareholders of listed companies for the half year 2023 is expected to be a loss of 22.5 million yuan to 29 million yuan, with profit of 246.962 million yuan for the same period last year; net profit after deducting non-recurring profit and loss is a loss of 24.11 million yuan to 30.61 million yuan, compared with profit of 13.8868 million yuan for the same period last year. Main reasons: 1. Affected by increased competition in the market, sales of the company's leading products, high-vitamin B2 products, declined, and sales revenue and net profit all declined. 2. Expand marketing channels and restricted stocks during the reporting period
Company Q&A | Guangji Pharmaceutical: The unit of measure for the company's overseas business is the US dollar, and the devaluation of the RMB has a positive effect on the company's exchange earnings
GLONGHUI June 30丨Some investors asked Guangji Pharmaceutical on the interactive platform: What is the impact of the devaluation of the RMB on exports? Guangji Pharmaceutical responded: The unit of measure for the company's overseas business is the US dollar, and the devaluation of the RMB has a positive effect on the company's exchange earnings.
Guangji Pharma to Establish Joint Innovation Laboratory With Jiangnan University
Hubei Guangji Pharmaceutical (SHE:000952) signed a strategic alliance with China's Jiangnan University to establish a joint innovation laboratory, according to a filing on Thursday. The laboratory wil
Guangji Pharmaceutical (000952.SZ) plans to jointly establish a joint innovation laboratory with Jiangnan University to carry out in-depth cooperative layout
According to the Zhitong Finance App, Guangji Pharmaceutical (000952.SZ) announced that the company recently signed the “Hubei Guangji Pharmaceutical Co., Ltd. - Jiangnan University Strategic Cooperation Agreement on Establishing a Joint Innovation Laboratory” with Jiangnan University. The two parties plan to jointly establish the “Hubei Guangji Pharmaceutical Co., Ltd. - Jiangnan University Joint Innovation Laboratory” to specialize in research on key technologies for green manufacturing and biosynthesis of functional polysaccharides and functional proteins (such as breast milk oligosaccharides, etc.). According to reports, Jiangnan University is a university directly under the Ministry of Education, a national “211 project” focused on building colleges and universities with first-class disciplines. It currently has food science
Guangji Pharmaceutical signed a joint innovation laboratory with Jiangnan University
Gelonghui, June 14丨Guangji Pharmaceutical announced that the company and Jiangnan University have signed a joint innovation laboratory to conduct research on key technologies for the green manufacturing and biosynthesis of functional polysaccharides and functional proteins (such as breast milk oligosaccharides, etc.).
Guangji Pharmaceutical (000952.SZ) established a subsidiary as a vehicle for developing major health industries such as traditional Chinese medicine and health products
According to the Zhitong Finance App, Guangji Pharmaceutical (000952.SZ) issued an announcement. Based on the company's “API drug+formulation+big health” development plan and “endogenous expansion+platform development+strong chain repair mergers and acquisitions” development strategy, to achieve breakthroughs in the company's major health industries such as traditional Chinese medicine and health products, the company has set up a wholly-owned subsidiary, Hubei Guangji Health Technology Co., Ltd. as a vehicle for developing big health industries such as traditional Chinese medicine and health products. After preliminary research and careful judgment, the company plans to invest 10 million yuan to establish a wholly-owned subsidiary. Recently, Hubei Guangji Health Technology Co., Ltd., a wholly-owned subsidiary, has completed commercial and commercial registration.
Guangji Pharmaceutical (000952.SZ): Net loss of 44,038,500 yuan in the first quarter
Gelonhui, April 27, 丨 Guangji Pharmaceutical (000952.SZ) announced its report for the first quarter of 2023. Revenue for the reporting period was 115 million yuan, down 13.49% from the previous year; net profit attributable to shareholders of listed companies was -44,0385 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -44.932 million yuan; basic earnings per share were -0.1244 yuan.
Analysis
Price Target
No Data
